Clinical Trials Logo

Pancreatic Neoplasms clinical trials

View clinical trials related to Pancreatic Neoplasms.

Filter by:

NCT ID: NCT04132505 Recruiting - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

Start date: October 22, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the best dose of hydroxychloroquine when given together with binimetinib in treating patients with KRAS gene mutated pancreatic cancer that has spread to other places in the body (metastatic). Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hydroxychloroquine may prevent autophagy, a normal process in which a cell destroys proteins and other substances which may lead to cell death. Autophagy may prevent normal cells from developing into tumor cells, but it may also protect tumor cells by destroying anticancer drugs or substances taken up by them. Giving hydroxychloroquine together with binimetinib may work better in treating patients with pancreatic cancer compared to binimetinib alone.

NCT ID: NCT04131192 Terminated - Pancreatic Cancer Clinical Trials

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Start date: November 11, 2019
Phase: Phase 1
Study type: Interventional

This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.

NCT ID: NCT04130399 Withdrawn - Pancreatic Cancer Clinical Trials

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Start date: July 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal adenocarcinoma (PDAC) in order to intensify local therapy and improve outcomes.

NCT ID: NCT04128332 Active, not recruiting - Cancer of Pancreas Clinical Trials

Pre-operative Stereotactic Ablative Body Radiotherapy Followed by Immediate Surgery for Pancreatic Cancer

PORTICO-SABR
Start date: October 26, 2020
Phase: N/A
Study type: Interventional

A window of opportunity feasibility study assessing pre-operative stereotactic ablative body radiotherapy followed by immediate surgery in pancreatic adenocarcinoma.

NCT ID: NCT04123574 Withdrawn - Pancreatic Cancer Clinical Trials

A Pilot Study of BXCL701 in Patients With Pancreatic Cancer

Start date: October 15, 2019
Phase: Early Phase 1
Study type: Interventional

A study to assess the biochemical and immunomodulatory effects of BXCL701 in pancreatic cancer.

NCT ID: NCT04117958 Terminated - Clinical trials for MUC17-positive Solid Tumors

Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers

Start date: January 20, 2020
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of AMG 199 in adult subjects and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).

NCT ID: NCT04117087 Recruiting - Colorectal Cancer Clinical Trials

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Start date: May 28, 2020
Phase: Phase 1
Study type: Interventional

Phase 1 study for patients with resected PDAC after neoadjuvant and/ or adjuvant chemotherapy and/or radiation, as well as patients with metastatic colorectal cancer who have exposure to 2 or more lines of chemotherapy, to evaluate safety and the immune response to pooled mutant-KRAS peptide vaccine (KRAS peptide vaccine) with poly-ICLC adjuvant in combination with nivolumab and ipilimumab.

NCT ID: NCT04116073 Recruiting - Clinical trials for Pancreatic Cancer Non-resectable

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer

Start date: April 9, 2020
Phase: Phase 2
Study type: Interventional

Phase 2 study to evaluate the clinical activity of INCMGA00012 in patients with Unresectable or metastatic Adenosquamous Pancreatic or Ampullary Cancer.

NCT ID: NCT04115254 Suspended - Prostate Cancer Clinical Trials

Stereotactic Magnetic Resonance Guided Radiation Therapy

Start date: October 22, 2019
Phase: N/A
Study type: Interventional

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. - The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. - Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

NCT ID: NCT04115163 Recruiting - Clinical trials for Metastatic Pancreatic Adenocarcinoma

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Start date: June 24, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well a biologically optimized infusion schedule of gemcitabine and nab-paclitaxel works in treating patients with pancreatic cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Altering the timing of the nab-paclitaxel infusion may improve response in patients with pancreatic cancer.